10 results
P
adult systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) patients
I/C
EMBASE/PubMed search and meta-analysis using Peto's odds ratios, AIHA +ve vs. AIHA -ve patients
O
pooled prevalence (PP) of IgG/IgM anticardiolipin (aCL) and lupus anticoagulant (LA)
P
patients with spondyloarthritis
I/C
biologic therapy, placebo
O
risk of infections, including serious infections, upper respiratory tract infection, nasopharyngitis, and Candida infection
P
patients with rheumatoid arthritis (RA)
I/C
biological therapy, non-biologics
O
risk of tuberculosis
P
patients with dry-eye disease (DED)
I/C
topical cyclosporin A (CsA), artificial tears (ATs)
O
tear-breakup time, fluorescein-staining score, ocular surface-disease index, adverse events
P
Anterior cranial vault expansion, Posterior cranial vault expansion
I/C
Fronto-orbital advancement (anterior cranial vault expansion), Posterior cranial vault expansion, Anterior cranial vault expansion vs. posterior cranial vault expansion
O
Reoperation, Complications
P
kidney failure patients undergoing peritoneal dialysis
I/C
icodextrin-containing PD regimens, glucose-only PD regimens
O
ultrafiltration, fluid overload, mortality, peritoneal glucose absorption, fasting plasma glucose, hemoglobin A1c
P
patients with borderline ovarian tumors (BOT)
I/C
restaging surgery, incomplete surgery
O
recurrence and mortality rates
P
patients with established coronary artery disease (CAD)
I/C
colchicine, placebo or usual care
O
cardiovascular (CV) death, myocardial infarction (MI), or stroke
P
infants, children
I/C
paracetamol, ibuprofen, paracetamol vs. ibuprofen
O
asthma exacerbations, wheezing